Patient Power founder caught up with leading CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Watch as Dr. Kipps reviews data, including the use of ibrutinib (Imbruvica) in the frontline setting, the role of chemotherapy and an update on emerging therapies.
Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo